A Test-retest Study to Assess Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of AH111585 (18F) Injection.

Inclusion Criteria:

- The subject has been diagnosed with at least one solid primary or metastatic tumor
greater than 2.0 cm in diameter, including but not limited to NSCLC, RCC, GBM,
melanoma, sarcoma, breast and H&N cancers.

- The subject has received clinical routine imaging diagnostic work-up within 8 weeks
prior to the first [18F]AH111585 PET scan.

- The subject has a clinically acceptable (as judged by the investigator) physical
examination at screening and is capable of self-care.

Exclusion Criteria:

- The subject has known hyper- or hypo-coagulation syndromes.

- The subject has received chemotherapy within 3 weeks, or received radiotherapy,
surgery or any other treatment against cancer within 4 weeks prior to the first
[18F]AH111585 PET scan.

- The subject is scheduled to undergo chemotherapy, radiotherapy, surgery or any other
treatment against cancer between the first and second [18F]AH111585 PET scans.

- The subject is scheduled to undergo biopsy for the target tumour between the first
and second [18F]AH111585 PET scans.

- The subject has intra-hepatic tumour(s) only.

- For the immuno-histochemistry group, the subject's target tumour has been biopsied
less than or equal to 1 week prior to the first [18F]AH111585 PET scan.